Alzheimer Disease Clinical Trials in St Louis, Missouri

16 studies are recruiting for alzheimer disease in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 1667, St Louis, Missouri

   Locations

   162 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011732 on ClinicalTrials.gov

2. Study to Understand Novel Biomarkers in Researching Dementia

   The purpose of this study is to determine the relationships between amyloid, tau, and neurodegeneration biomarkers in the blood and the presence of Alzheimer's disease (AD) pathology, clinical cognitive decline, and diagnosis. We aim to understand how well blood-based biomarkers can diagnose and pr…

   Stage

   Not phased

   Ages

   60 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT06547099 on ClinicalTrials.gov

3. A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

   The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

   Stage

   Phase 4

   Ages

   50 and older

   Site

   Tekton Research Saint Louis Psychiatry, St Louis, Missouri

   Locations

   14 in total

   Run by

   Alpha Cognition, Inc

   See if you can join NCT07633470 on ClinicalTrials.gov

4. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Tekton Research, LLC - Saint Louis Psychiatry - PPDS, St Louis, Missouri

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

5. Sleep Trial to Prevent Alzheimer's Disease

   The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.

   Stage

   Phase 2

   Ages

   65 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   University of Minnesota

   See if you can join NCT04629547 on ClinicalTrials.gov

6. DORA and LP in Alzheimer's Disease Biomarkers

   The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

   Stage

   Phase 2

   Ages

   65 and older

   Site

   Washington University in St. Louis, School of Medicine, St Louis, Missouri

   Run by

   University of Minnesota

   See if you can join NCT06274528 on ClinicalTrials.gov

7. Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1

   This study involves a brain positron emission tomography (PET) scan with a new, investigational radioactive tracer called [11C]-CS1P1 to identify inflammation in the brain by testing with healthy older adults and with cognitively impaired older adults.

   Stage

   Not phased

   Ages

   50 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT06129838 on ClinicalTrials.gov

8. Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

   The purpose of this research study is to determine the safety of a radiotracer 18F-Fluselenamyl using positron emission tomography (PET) imaging.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT06439992 on ClinicalTrials.gov

9. F 18 T807 Tau PET Imaging of Alzheimer's Disease

   A single-center, open-label baseline controlled imaging study designed to assess whether brain tau fibril uptake of flortaucipir as measured by PET correlates with cognitive status of individuals with and without brain tau fibrils.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Tammie L. S. Benzinger, MD, PhD

   See if you can join NCT02414347 on ClinicalTrials.gov

10. Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

    To identify factors that signal the transition from asymptomatic (preclinical) to symptomatic Alzheimer disease (AD).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Tammie L. S. Benzinger, MD, PhD

    See if you can join NCT04579120 on ClinicalTrials.gov

11. Clinical Trial on Agitation in Alzheimer's Dementia

    The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.

    Stage

    Phase 2

    Ages

    60 and older

    Site

    Tekton Research LLC, St Louis, Missouri

    Locations

    31 in total

    Run by

    IGC Pharma, LLC

    See if you can join NCT05543681 on ClinicalTrials.gov

12. Trial-Ready Cohort-Down Syndrome (TRC-DS)

    The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 550 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-D…

    Stage

    Not phased

    Ages

    25 to 55

    Site

    Washington University, St. Louis, St Louis, Missouri

    Locations

    22 in total

    Run by

    University of Southern California

    See if you can join NCT04165109 on ClinicalTrials.gov

13. Late Onset Alzheimer's Disease

    The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to…

    Stage

    Not phased

    Ages

    55 and older

    Site

    Joanne Norton, St Louis, Missouri

    Locations

    12 in total

    Run by

    Columbia University

    See if you can join NCT05010603 on ClinicalTrials.gov

14. Alzheimer"s Imaging Biomarkers in Obesity

    High body fat at midlife, as evidenced by overweight or obese body mass index (BMI), is increasingly understood as a risk factor for Alzheimer's disease. However, the underlying processes and mechanisms that may underlie this risk remains unknown. With this project, the Investigator proposes to cre…

    Stage

    Not phased

    Ages

    40 to 60

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Cyrus A Raji

    See if you can join NCT05077579 on ClinicalTrials.gov

15. A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK

    This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve ce…

    Stage

    Phase 1

    Ages

    21 to 80

    Site

    Washington University in St. Louis, St Louis, Missouri

    Locations

    2 in total

    Run by

    University College, London

    See if you can join NCT06372821 on ClinicalTrials.gov

16. Imaging Biomarkers in Preclinical and Symptomatic AD

    The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Tammie L. S. Benzinger, MD, PhD

    See if you can join NCT04134923 on ClinicalTrials.gov